Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Noul Demonstrates AI-Driven On-Site Diagnostics Platform at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022

Noul Co. More...

, Ltd. (Gyeonggi-do, Korea) is demonstrating the world’s first integrated device featuring fully-automated sample preparation and AI-based diagnosis at the 2022 edition of MEDICA being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Noul is demonstrating miLab, which is the world’s first all-in-one, fully-automated device which can process sample preparation and AI diagnostic in one workflow. miLab integrates cutting edge technologies from computer vision AI, bio, hardware and software engineering. From automated sample preparation to imaging and AI analysis, the miLab platform combines the gold standard in blood diagnostics into a fully automated benchtop platform. Combined with embedded AI and the company’s patented Next Generation Staining and Immunostaining (NGSI) cartridges, miLab provides an accurate analysis in 20 minutes using just 5 uL of blood. NGSI, the patented solid-based staining technology can replace the current liquid-based sample preparation methods and possess the potential to expand applicabilities to other diagnostic areas. NGSI technology eliminates the liquid usage in the sample staining process and can complete it in only a few minutes using a single step stamping method.

miLab provides superior accuracy compared to the competing technologies by combining multi-focus imaging and the state-of-the-art AI algorithm. The company’s AI can perfectly replicate the diagnosis of an expert microscopist without the errors and deviations. miLab’s AI algorithm analyzes multi-layered digital images of smeared blood cells to achieve 99%+ specificity in order to classify and detect parasite-infected cells. Among Noul’s offerings is the miLab Malaria which detects different stages of Plasmodium Falciparum and Plasmodium Vivax species and the miLab BCM which provides a morphology-based white blood cell (WBC) differential and cell count estimations, allowing decentralized health facilities to perform a WBC differential count and CBC estimation.

Related Links:
Noul Co., Ltd.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.